Wegovy is Novo Nordisk’s FDA-approved semaglutide for chronic weight management, approved June 2021 at the 2.4 mg weekly dose.

Ozempic is Novo Nordisk’s brand-name semaglutide injection approved by the FDA in December 2017 for type 2 diabetes.

Switching between Ozempic, Wegovy, and compounded semaglutide is straightforward because the active ingredient is identical.

Compounded semaglutide is a sterile injectable peptide that requires refrigeration between 36°F and 46°F (2°C-8°C).

Compounded semaglutide vials should be refrigerated between 36-46°F (2-8°C) until first use.

Most semaglutide side effects are gastrointestinal, mild to moderate, and concentrated in the first 8-12 weeks. In STEP 1 (Wilding et al.

Average weight loss on semaglutide 2.4 mg weekly, from STEP 1 (Wilding et al.

Introduction Compounded semaglutide is the same active ingredient as Wegovy® and Ozempic®, made by 503A or 503B pharmacies and dispensed through telehealth platforms like…

Introduction Compounded semaglutide quality is verified through batch testing for potency, sterility, and endotoxin levels, conducted on samples from each compounding lot. Reputable 503A…